ZhenGe Biotech and ColorTech Bio Announce Strategic Collaboration to Advance Biologics R&D and Detection Capabilities

On March 25, 2021, Shanghai Zhenge Biotechnology Co., Ltd. (hereinafter referred to as “Zhenge Biotech”) and Lychix (Suzhou) Biotechnology Co., Ltd. (hereinafter referred to as “Lychix”) jointly signed a strategic cooperation agreement.

Lychix will provide to Shanghai Zhenge Biotechnology Co., Ltd.A digital biology product and service portfolio, including a single-molecule multiplex protein detection platform, with future product lines to be developed in deep collaboration with Shanghai Zhenge Biotechnology Co., Ltd., both parties will jointly develop the technologies required by Shanghai Zhenge Biotechnology Co., Ltd. in the research and development of large-molecule biologics.

The single-molecule multiplex protein detection platform provided by Lychix enables biomarker detection at the fg/mL level. Compared with conventional detection methods, it can be integrated throughoutPreclinical cytokine assays involved in CDMO services and the monitoring of biologic drug metabolism in clinical settings will achieve high-precision detection under stringent conditions with extremely limited sample volumes and protein content.

Zhenge Biotechnology boasts extensive experience in assisting new drug developers in the development of large-molecule therapeutics and their successful commercialization. The company has independently developed an integrated platform encompassing cell line development, cell culture processes, and media formulation. Furthermore, Zhenge Biotechnology is continuously exploring the integration and translation of novel technologies and methodologies into its proprietary platform, aiming to deliver more cutting-edge and precise solutions to clients while fully leveraging the advantages of its integrated CDMO technology platform.

Under this collaboration, Shanghai Zhenge Biotechnology Co., Ltd. will establish an ultra-high-sensitivity multiplex protein detection technology platform, and will subsequently collaborate with LychixOther High-Resolution Life Science Product Linesengage in deep collaboration to better serve the existing customer base of Shanghai Zhenge Biotechnology Co., Ltd. Lychix will also accelerate the development of products related to drug R&D, enhancing the competitive advantages of its R&D pipeline in terms of time, efficiency, and cost. This collaboration is conducive to both parties leveraging their respective strengths, sharing resources, complementing each other’s advantages, and achieving mutual benefits and win-win outcomes.

Shanghai Zhenge Biotechnology Co., Ltd. (hereinafter referred to as “Zhenge Biotech”), established in 2017, is a national high-tech enterprise registered in the Lingang New Area of the China (Shanghai) Pilot Free Trade Zone. Zhenge Biotech operates R&D centers in the Zhoupu International Medical Park in Shanghai and in Maryland, USA, and maintains cGMP pilot-scale and commercial manufacturing facilities in the Lingang New Area of Shanghai. The company’s core business focuses on CDMO services for large-molecule biologics, as well as the development and production of mammalian cell culture media. Specific offerings include druggability assessment of large-molecule drugs, comprehensive CMC clinical filing support, cell line development, process development and optimization, pilot-scale manufacturing, clinical sample production, commercial CMO services, process characterization and validation studies, analytical testing services, and the formulation development and commercial production of cell culture media. By providing integrated CDMO services spanning from preclinical research to commercial manufacturing, along with domestically produced customized cell culture media products, Zhenge Biotech aims to facilitate and accelerate the R&D and industrialization of large-molecule biologics for pharmaceutical companies both in China and abroad.

Lychix (Suzhou) Biotechnology Co., Ltd. was established in Suzhou in 2018, with R&D and sales centers located at the Suzhou BioBAY and the North Carolina Biotechnology Center in the United States. Leveraging an advanced interdisciplinary technology platform spanning optics, microfluidics, materials science, semiconductors, and biomedicine, Lychix is a life sciences company dedicated to advancing the clinical and pharmaceutical application of next-generation digital multi-omics biophysical technologies.